TY - STD TI - Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–e220. ID - ref1 ER - TY - STD TI - Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–5. ID - ref2 ER - TY - JOUR AU - Kim, M. H. AU - Johnston, S. S. AU - Chu, B. -. C. AU - Dalal, M. R. AU - Schulman, K. L. PY - 2011 DA - 2011// TI - Estimation of total incremental health care costs in patients with atrial fibrillation in the United States JO - Circ Cardiovasc Qual Outcomes VL - 4 UR - https://doi.org/10.1161/CIRCOUTCOMES.110.958165 DO - 10.1161/CIRCOUTCOMES.110.958165 ID - Kim2011 ER - TY - STD TI - Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101–98. ID - ref4 ER - TY - JOUR AU - Wolf, P. A. AU - Abbott, R. D. AU - Kannel, W. B. PY - 1991 DA - 1991// TI - Atrial fibrillation as an independent risk factor for stroke: the Framingham Study JO - Stroke VL - 22 UR - https://doi.org/10.1161/01.STR.22.8.983 DO - 10.1161/01.STR.22.8.983 ID - Wolf1991 ER - TY - JOUR AU - Fitch, K. AU - Broulette, J. AU - Pyenson, B. AU - Iwasaki, K. AU - Kwong, W. J. PY - 2012 DA - 2012// TI - Erratum: utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillation JO - Am Health Drug Benefits VL - 5 ID - Fitch2012 ER - TY - STD TI - Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke. 1996;27:1760–4. ID - ref7 ER - TY - JOUR AU - Hart, R. G. AU - Pearce, L. A. AU - Aguilar, M. I. PY - 2007 DA - 2007// TI - Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation JO - Ann Intern Med VL - 146 UR - https://doi.org/10.7326/0003-4819-146-12-200706190-00007 DO - 10.7326/0003-4819-146-12-200706190-00007 ID - Hart2007 ER - TY - JOUR AU - Albers, G. W. AU - Sherman, D. G. AU - Gress, D. R. AU - Paulseth, J. E. AU - Petersen, P. PY - 1991 DA - 1991// TI - Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials JO - Ann Neurol VL - 30 UR - https://doi.org/10.1002/ana.410300402 DO - 10.1002/ana.410300402 ID - Albers1991 ER - TY - JOUR AU - Kim, C. K. AU - Jung, S. AU - Yoon, B. -. W. PY - 2013 DA - 2013// TI - Practical issues to prevent stroke associated with non-valvular atrial fibrillation JO - J Stroke VL - 15 UR - https://doi.org/10.5853/jos.2013.15.3.144 DO - 10.5853/jos.2013.15.3.144 ID - Kim2013 ER - TY - STD TI - Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:546S–92S. ID - ref11 ER - TY - JOUR AU - Lin, P. PY - 2005 DA - 2005// TI - Reviewing the reality: why we need to change JO - Eur Heart J VL - 7 UR - https://doi.org/10.1093/eurheartj/sui031 DO - 10.1093/eurheartj/sui031 ID - Lin2005 ER - TY - JOUR AU - Buckingham, T. A. AU - Hatala, R. PY - 2002 DA - 2002// TI - Anticoagulants for atrial fibrillation: why is the treatment rate so low? JO - Clin Cardiol VL - 25 UR - https://doi.org/10.1002/clc.4960251003 DO - 10.1002/clc.4960251003 ID - Buckingham2002 ER - TY - JOUR AU - Ahrens, I. AU - Lip, G. Y. H. AU - Peter, K. PY - 2010 DA - 2010// TI - New oral anticoagulant drugs in cardiovascular disease JO - Thromb Haemost VL - 104 UR - https://doi.org/10.1160/TH09-05-0327 DO - 10.1160/TH09-05-0327 ID - Ahrens2010 ER - TY - STD TI - Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. ID - ref15 ER - TY - STD TI - Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. ID - ref16 ER - TY - STD TI - Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. ID - ref17 ER - TY - JOUR AU - Chan, L. AU - Pisano, M. PY - 2015 DA - 2015// TI - Edoxaban (Savaysa): a factor xa inhibitor JO - P T VL - 40 ID - Chan2015 ER - TY - STD TI - Kalus JS. Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions. Drugs Context. 2013;2013:212251. doi:10.7573/dic.212251. eCollection 212013 Apr 212216 ID - ref19 ER - TY - JOUR AU - Cheng, J. W. AU - Barillari, G. PY - 2014 DA - 2014// TI - Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions JO - J Clin Pharm Ther VL - 39 UR - https://doi.org/10.1111/jcpt.12122 DO - 10.1111/jcpt.12122 ID - Cheng2014 ER - TY - STD TI - Stöllberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz. 2015; ID - ref21 ER - TY - STD TI - Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011;2011(57):1330–7. ID - ref22 ER - TY - STD TI - Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–64. ID - ref23 ER - TY - JOUR AU - Seeger, J. D. AU - Bykov, K. AU - Bartels, D. B. AU - Huybrechts, K. AU - Zint, K. AU - Schneeweiss, S. PY - 2015 DA - 2015// TI - Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation JO - Thromb Haemost VL - 114 UR - https://doi.org/10.1160/TH15-06-0497 DO - 10.1160/TH15-06-0497 ID - Seeger2015 ER - TY - JOUR AU - Kamel, H. AU - Johnston, S. C. AU - Easton, J. D. AU - Kim, A. S. PY - 2012 DA - 2012// TI - Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack JO - Stroke VL - 43 UR - https://doi.org/10.1161/STROKEAHA.111.641027 DO - 10.1161/STROKEAHA.111.641027 ID - Kamel2012 ER - TY - STD TI - Francis K, Yu C, Alvrtsyan H, Sander S, Ghosh S, Rao Y, et al. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2015;31:2189–95. doi:10.1185/03007995.03002015.01092124. Epub 03002015 Sep 03007924 ID - ref26 ER - TY - STD TI - Bancroft T, Lim J, Wang C, Sander SD, Swindle JP. Health care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with dabigatran versus warfarin in the United States. Clin Ther. 2016;38:545–556.e546. doi:10.1016/j.clinthera.2016.1001.1008. Epub 2016 Feb 1015. http://www.clinicaltherapeutics.com/article/S0149-2918(16)00021-7/fulltext. UR - http://www.clinicaltherapeutics.com/article/S0149-2918(16)00021-7/fulltext ID - ref27 ER - TY - STD TI - Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes. 2013;6:567–74. ID - ref28 ER - TY - JOUR AU - Deyo, R. A. AU - Cherkin, D. C. AU - Ciol, M. A. PY - 1992 DA - 1992// TI - Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases JO - J Clin Epidemiol VL - 45 UR - https://doi.org/10.1016/0895-4356(92)90133-8 DO - 10.1016/0895-4356(92)90133-8 ID - Deyo1992 ER - TY - JOUR AU - Elixhauser, A. AU - Steiner, C. AU - Harris, D. R. AU - Coffey, R. M. PY - 1998 DA - 1998// TI - Comorbidity measures for use with administrative data JO - Med Care VL - 36 UR - https://doi.org/10.1097/00005650-199801000-00004 DO - 10.1097/00005650-199801000-00004 ID - Elixhauser1998 ER - TY - JOUR AU - Gage, B. F. AU - Waterman, A. D. AU - Shannon, W. AU - Boechler, M. AU - Rich, M. W. AU - Radford, M. J. PY - 2001 DA - 2001// TI - Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JO - JAMA VL - 285 UR - https://doi.org/10.1001/jama.285.22.2864 DO - 10.1001/jama.285.22.2864 ID - Gage2001 ER - TY - JOUR AU - Lip, G. Y. AU - Nieuwlaat, R. AU - Pisters, R. AU - Lane, D. A. AU - Crijns, H. J. PY - 2010 DA - 2010// TI - Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation JO - Chest VL - 137 UR - https://doi.org/10.1378/chest.09-1584 DO - 10.1378/chest.09-1584 ID - Lip2010 ER - TY - JOUR AU - Enriquez, A. AU - Baranchuk, A. AU - Redfearn, D. AU - Simpson, C. AU - Abdollah, H. AU - Michael, K. PY - 2015 DA - 2015// TI - Dabigatran for the prevention and treatment of thromboembolic disorders JO - Expert Rev Cardiovasc Ther VL - 13 UR - https://doi.org/10.1586/14779072.2015.1034692 DO - 10.1586/14779072.2015.1034692 ID - Enriquez2015 ER - TY - JOUR AU - Berger, R. AU - Salhanick, S. D. AU - Chase, M. AU - Ganetsky, M. PY - 2013 DA - 2013// TI - Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin JO - Ann Emerg Med VL - 61 UR - https://doi.org/10.1016/j.annemergmed.2013.02.008 DO - 10.1016/j.annemergmed.2013.02.008 ID - Berger2013 ER -